Search

Your search keyword '"Nelson, Harold S"' showing total 1,216 results
Start Over Author "Nelson, Harold S"
1,216 results on '"Nelson, Harold S"'

253. List of Contributors

Author

Abzug, Mark J., Akdis, Cezmi A., Allen, Katrina, Bacharier, Leonard B., Ballow, Mark, Bartholow, Ashton, Becker, Allan, Behrens, Edward M., Bender, Bruce G., Berin, M. Cecilia, Bielory, Brett P., Bielory, Leonard, Bock, S. Allan, Boguniewicz, Mark, Bonilla, Francisco A., Burks, A. Wesley, Bush, Andrew, Chan, Kenny H., Chehade, Mirna, Chiriac, Anca M., Cicutto, Lisa, Collins, Samuel A., Covar, Ronina A., Davis, Benjamin P., Dedeoglu, Fatma, Demoly, Pascal, Eggleston, Peyton A., Eisenberg, Robert, Fleisher, Thomas A., Fonacier, Luz, Gentile, Deborah A., Gern, James E., Groetch, Marion, Halken, Susanne, Hamilton, Robert G., Hollams, Elysia M., Holland, Steven M., Holloway, John W., Holt, Patrick G., Høst, Arne, Jackson, Daniel J., Jones, Stacie M., Kattan, Meyer, Kelly, Brian T., Kelly, Kevin J., Kim, Susan, Kohn, Donald B., Lederman, Howard M., Lehman, Heather K., Lemanske, Robert F., Jr, Leung, Donald Y.M., Liacouras, Chris A., Liu, Andrew H., Lockett, Gabrielle A., Markowitz, Jonathan E., Martinez, Fernando D., Matsui, Elizabeth C., Mazer, Bruce D., Milgrom, Henry, Muir, Amanda B., Nelson, Harold S., Nichols, David P., Notarangelo, Luigi D., Novak, Natalija, Nowak-Węgrzyn, Anna, Oettgen, Hans C., Olin, J. Tod, Oliveira, Joao Bosco, Oude Elberink, Hanneke (Joanne) N.G., Palomares, Oscar, Phipatanakul, Wanda, Pleskovic, Nicole, Prescott, Susan, Rosenzweig, Sergio D., Rothenberg, Marc E., Sampson, Hugh A., Sheehan, William J., Sicherer, Scott H., Simons, F. Estelle R., Skoner, David P., Spahn, Joseph D., Strunk, Robert C., Sullivan, Kathleen E., Sundel, Robert P., Szefler, Stanley J., Torgerson, Troy R., von Mutius, Erika, Wagner, Rudolph S., Wang, Julie, Weber, Richard W., Wood, Robert A., and Zuraw, Bruce L.

Published
2016
Full Text
View/download PDF

254. Comments on the salmeterol multicenter asthma research trial

Author

Seymour, Sally M., Sullivan, Eugene J., Chowdhury, Badrul A., Meyer, Robert J., Davi, Ruthanna C., Nelson, Harold S., and Dorinsky, Paul M.

Subjects
Salmeterol -- Usage, Salmeterol -- Research, Asthma -- Drug therapy, Health
Published
2006

255. Cause of death in the SMART Trial

Author

Williams, Craig, Nelson, Harold S., and Dorinsky, Paul M.

Subjects
Death -- Causes of, Salmeterol -- Usage, Salmeterol -- Research, African Americans -- Health aspects, African Americans -- Research, Health
Published
2006

256. The salmeterol multicenter asthma research trial

Author

Sears, Malcolm R., Nelson, Harold S., and Dorinsky, Paul M.

Subjects
Salmeterol -- Research, Salmeterol -- Usage, Asthma -- Research, Asthma -- Drug therapy, Health
Published
2006

268. Reply

Author

Blaiss, Michael, primary, Nelson, Harold S., additional, Durham, Stephen R., additional, Dahl, Ronald, additional, and Bufe, Albrecht, additional

Published
2011
Full Text
View/download PDF

272. Commentary 2

Author

Weber, Richard W. and Nelson, Harold S.

Published
1985

284. Sub-Lingual Immunotherapy

Author

Canonica, G. Walter, primary, Bousquet, Jean, additional, Casale, Thomas, additional, Lockey, Richard F., additional, Baena-Cagnani, Carlos E., additional, Pawankar, Ruby, additional, Potter, Paul C., additional, Bousquet, Philippe J., additional, Cox, Linda S., additional, Durham, Stephen R., additional, Nelson, Harold S., additional, Passalacqua, Giovanni, additional, Ryan, Dermot P., additional, Brozek, Jan L., additional, Compalati, Enrico, additional, Dahl, Ronald, additional, Delgado, Luis, additional, van Wijk, Roy Gerth, additional, Gower, Richard G., additional, Ledford, Dennis K., additional, Filho, Nelson Rosario, additional, Valovirta, Erkka J., additional, Yusuf, Osman M., additional, Zuberbier, Torsten, additional, Akhanda, Wahiduzzaman, additional, Almarales, Raul Castro, additional, Ansotegui, Ignacio, additional, Bonifazi, Floriano, additional, Ceuppens, Jan, additional, Chivato, Tomás, additional, Dimova, Darina, additional, Dumitrascu, Diana, additional, Fontana, Luigi, additional, Katelaris, Constance H., additional, Kaulsay, Ranbir, additional, Kuna, Piotr, additional, Larenas-Linnemann, Désirée, additional, Manoussakis, Manolis, additional, Nekam, Kristof, additional, Nunes, Carlos, additional, O'Hehir, Robyn, additional, Olaguibel, José M., additional, Onder, Nerin Bahceciler, additional, Park, Jung Won, additional, Priftanji, Alfred, additional, Puy, Robert, additional, Sarmiento, Luis, additional, Scadding, Glenis, additional, Schmid-Grendelmeier, Peter, additional, Seberova, Ester, additional, Sepiashvili, Revaz, additional, Solé, Dírceu, additional, Togias, Alkis, additional, Tomino, Carlo, additional, Toskala, Elina, additional, Van Beever, Hugo, additional, and Vieths, Stefan, additional

Published
2009
Full Text
View/download PDF

299. Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial.

Author

Beasley, Richard W., Donohue, James F., Mehta, Rajendra, Nelson, Harold S., Clay, Michelle, Moton, Allen, Han-Joo Kim, and Hederer, Bettina M.

Abstract

Objective: To investigate the safety and efficacy of QMF149, a once-daily, fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol maleate and inhaled corticosteroid (ICS) mometasone furoate (MF) for the treatment of persistent asthma. The hypothesis was that QMF149 would not increase the risk of serious asthma exacerbations. Setting: 174 research centres in nine countries. Participants: 1519 adolescents and adults with persistent asthma who were treated or qualified for treatment with combination LABA/ICS were randomised, and 1508 were included in the intention-to-treat analysis. Intervention: Patients were randomised to QMF149 (indacaterol maleate 500 µg/MF 400 µg) or MF (400 µg) once daily via Twisthaler inhalation device in a double-blind, parallel-group study for 6-21 months. Primary and secondary outcome measures: The primary end point was time to first serious asthma exacerbation (resulting in hospitalisation, intubation or death). The key secondary end point was annual rate of exacerbations requiring systemic corticosteroids. Results: Treatment with QMF149 resulted in no significant difference in time to first serious exacerbation compared to MF (2 (0.3%) vs 6 events (0.8%); difference -0.52 percentage point; 95% CI -1.25 to 0.21, p=0.160, HR=0.31; 95% CI 0.06 to 1.54, p=0.151). QMF149 significantly reduced the annual rate of exacerbations requiring systemic corticosteroids (rate ratio=0.71; 95% CI 0.55 to 0.90, p=0.005). Proportions of patients experiencing adverse events were similar across groups (74.0% in the QMF149 group and 73.4% in the MF group). Serious adverse events occurred in 4% and 5.8% of patients in the QMF149 and MF groups, respectively. Conclusions: No significant difference was observed in the primary outcome of time to first serious asthma exacerbation in patients treated with QMF149 compared with patients treated with MF. Long-term treatment with QMF149 once daily had a favourable safety/efficacy profile in adolescent and adult patients with persistent asthma. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

300. Oral/sublingual Phleum pretense grass tablet (Grazax/Grastek) to treat allergic rhinitis in the USA.

Author

Nelson, Harold S

Subjects
GRASSES, HAY fever treatment, PHLEUM, SUBLINGUAL immunotherapy, PUBLIC health, THERAPEUTICS
Abstract

With the approval of two grass tablets and one ragweed tablet for sublingual immunotherapy (SLIT) by the US FDA in April 2014, the practice of allergy immunotherapy (AIT) in the USA has dramatically changed. Until this time, there were no approved allergen extracts for sublingual administration and physicians who prescribed SLIT for their patients did so without full knowledge of proper dosing or assurance of its safety. Now sublingual allergen tablets are available that have proven safe and effective doses. This article describes, in detail, the studies that have been conducted with a timothy grass SLIT tablet and draws some comparisons to the alternative 5-grass SLIT tablet. It also attempts to predict what will be the impact of the introduction of these tablets on the practice of AIT in the USA over the next few years. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results